Mepolizumab in eosinophilic disorders

Abstract

Mepolizumab (Bosatria^®, GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 κ type, which targets human IL-5 and thus prevents its interaction with the α-chain of the IL-5 receptor. To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders. This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders.

Keywords::

• anti-IL-5
• eosinophilic gastrointestinal disorders
• eosinophils
• human
• IL-5
• mepolizumab

Acknowledgements

The authors would like to thank Lisa Lewallen for her administrative efforts in creating this manuscript.

Financial & competing interests disclosure

J Pablo Abonia is an Assistant Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center and is Co-Director of the Registry for Eosinophilic Gastrointestinal Disorders (REGID). J Pablo Abonia is currently a site principal investigator for a clinical trial for the anti-IL-5 drug, reslizumab, sponsored by Cephalon, Inc. J Pablo Abonia is funded as a co-investigator on NIH grant NIH/NIDDK R01 DK076894-03S1. Philip E Putnam is a Professor of Pediatrics and Medical Director of the Cincinnati Center for Eosinophilic Disorders (CCED) at the Cincinnati Children’s Hospital Medical Center. J Pablo Abonia and Philip E Putnam have also participated as investigators in clinical trials of mepolizumab. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.